Experimental
Survodutide (BI 456906)
The prediction game
Call it: rising or fading?
Where does Survodutide (BI 456906) stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 5.1/10
Survodutide lands at neutral because it pairs a genuinely exciting liver mechanism with an unfinished, investigational file and a grey-market-only supply. The practical read: if your main concern is serious fatty liver disease and you want the most direct hepatic action in the GLP-1 family, survodutide is the most interesting bet in the pipeline, with 62% biopsy-confirmed improvement on its best dose, per Sanyal 2024. But if your goal is weight loss, approved drugs already do more with a known supply chain. The neutral score reflects that balance: large effects and a unique mechanism on one side, no approval, topline-only Phase 3 data, a 20% dropout rate, and an unproven heart profile on the other. ✅ Best for: People focused on metabolic-associated fatty liver disease who value survodutide's direct glucagon-driven liver mechanism over a weight-only approach. Patients with significant weight to lose who also carry liver fat, where the dual benefit compounds. Type 2 diabetics interested in the combined glucose and weight effect shown against semaglutide, per Bluher 2024. Experimentally minded users who accept investigational status, can monitor liver enzymes, glucose, and heart rate, and will titrate slowly to manage nausea. Anyone willing to wait for the Phase 3 liver readout before drawing firm conclusions. ❌ Avoid if: You have a personal or family history of medullary thyroid cancer or MEN 2, matching the class warning, per Le Roux 2024. You have a baseline fast or irregular heartbeat, given the glucagon-driven heart-rate rise, per Dahl 2024. You have a history of pancreatitis, active gastrointestinal disease, or you are pregnant or breastfeeding. You want a proven, approved option, since survodutide is investigational with no cardiovascular outcome data. You cannot verify the identity and purity of grey-market material, because contaminated or mislabeled product can outweigh the drug's own risks.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Experimental
- Trend
- Begins with Edition 2
- Momentum
- 0.0%
- BioHarmony Score
- 5.1/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.